Table 1.
Baseline Characteristics of the Patients and Clinical Outcome
| n | % | |
|---|---|---|
| Sex | ||
| Female/male | 36/66 | 35.3/64.7 |
| Median age (IQR) | 69 (62–75) | |
| Baseline malignancy | ||
| Non-Hodgkin lymphoma | 38 | 37.3 |
| Plasma cell disorders | 26 | 25.5 |
| Chronic lymphoid leukemia | 18 | 17.6 |
| Acute myeloid leukemia | 8 | 7.8 |
| Myelodisplastic syndrome | 4 | 3.9 |
| Acute lymphoid leukemia | 3 | 2.9 |
| Hodgkin lymphoma | 2 | 2.0 |
| Chronic myeloid leukemia | 1 | 1.0 |
| Myelofibrosis | 1 | 1.0 |
| Polycythemia vera | 1 | 1.0 |
| Status malignancy at COVID-19 diagnosis | ||
| Controlled | 63 | 61.8 |
| Active | 38 | 37.3 |
| Unknown | 1 | 1.0 |
| Last antineoplastic treatment before COVID-19 | ||
| Immunochemotherapy | 58 | 56.9 |
| Targeted therapy | 14 | 13.7 |
| AlloHSCT | 8 | 7.8 |
| AutoHSCT | 3 | 2.9 |
| Conventional chemotherapy | 3 | 2.9 |
| Demethylating agents | 3 | 2.9 |
| Supportive measures | 3 | 2.9 |
| CAR-T | 2 | 2.0 |
| Immunotherapy | 1 | 1.0 |
| No treatment | 7 | 6.9 |
| Last vaccine before COVID-19 | ||
| Median days before COVID-19 diagnosis (IQR) | 42 (20–64) | |
| mRNA | 101 | 99.0 |
| Inactivated | 1 | 1.0 |
| SARS-CoV-2 variant | ||
| Delta | 1 | 1.0 |
| Omicron | 43 | 42.2 |
| BA 1 | 5 | 4.9 |
| BA 2 | 18 | 17.5 |
| BA 4/5 | 4 | 3.9 |
| Unknown | 16 | 15.7 |
| Not tested | 58 | 56.9 |
| COVID-19 severity | ||
| Asymptomatic | 10 | 6.9 |
| Mild infection | 49 | 48.0 |
| Severe infection | 39 | 38.2 |
| Critical infection | 4 | 3.9 |
| Neutrophils at COVID-19 diagnosis | ||
| ≥1000 cells/mm3 | 68 | 66.7 |
| Lymphocytes at COVID-19 diagnosis | ||
| ≥500 cells/mm3 | 60 | 58.8 |
| Stay during COVID-19 episode | ||
| Hospital | 39 | 38.2 |
| Length of stay | 10 (7–20) | |
| Due to COVID-19 | 31 | 30.4 |
| Oxygen administration | 22 | 21.6 |
| Home | 63 | 61.8 |
| COVID-19 treatment | ||
| No specific treatment reported | 46 | 45.1 |
| Antivirals ± convalescent plasma | 20 | 19.6 |
| Monoclonal antibodies ± convalescent plasma | 14 | 13.7 |
| Antivirals + monoclonal antibodies ± convalescent plasma | 12 | 11.8 |
| Corticosteroids | 10 | 9.8 |
| Outcome | ||
| Median observation time since COVID-19 diagnosis (IQR) | 54 (27–82) | |
| Alive Dead |
98 4 |
96.1 3.9 |
alloHSCT = allogeneic hematopoietic stem cell transplant; autoHSCT = autologous hematopoietic stem cell transplant; CAR-T = chimeric antigen receptor T-cells; IQR = interquartile range.